# Sanofi deepens respiratory franchise as earnings expectations come into focus

- Link: https://www.directorstalkinterviews.com/sanofi-deepens-respiratory-franchise-as-earnings-expectations-come-into-focus/4121261722
- Published: 2026-09-03T15:40:00+01:00
- Author: Amilia Stone

Sanofi is adding commercial depth to its respiratory portfolio in Spain, with developments
around Dupixent and Beyfortus coinciding with analyst expectations for higher earnings
per share in 2027. Together, the updates provide a useful indication of how the 
pharmaceutical group is translating established medicines into broader market access
and public healthcare demand.

Sanofi and Regeneron have announced the availability of Dupixent in Spain for adults
with uncontrolled chronic obstructive pulmonary disease, or COPD, who have elevated
levels of eosinophils in their blood. The biological medicine, whose active ingredient
is dupilumab, is being incorporated into Spain’s National Health System for use 
as an additional maintenance therapy in eligible patients whose disease remains 
inadequately controlled despite inhaled treatment.

The expansion into COPD increases the relevance of Dupixent within Sanofi’s respiratory
offering by addressing a defined subgroup of patients with evidence of type 2 inflammation.
This gives the company an additional route for extending the medicine’s use while
maintaining a targeted clinical approach based on patient characteristics.

The Spanish availability follows Phase 3 studies BOREAS and NOTUS, which evaluated
dupilumab in adults with uncontrolled COPD and evidence of type 2 inflammation. 
In the two trials, treatment was associated with reductions of 30% and 34%, respectively,
in the annualised rate of moderate or severe exacerbations compared with placebo
after 52 weeks. Improvements were also observed in lung function, symptoms and quality
of life.

Expanded reimbursement and availability can move a medicine from regulatory progress
towards practical adoption within a national healthcare system. The opportunity 
will depend on uptake among eligible patients and the extent to which clinicians
identify the specific inflammatory profile addressed by the treatment.

Sanofi is also seeing public-sector demand in Spain for nirsevimab, marketed as 
Beyfortus, which is used to protect infants against respiratory syncytial virus.
The Castilla-La Mancha regional health authority has formalised the purchase of 
15,000 doses from Sanofi Aventis for the 2026-2027 immunisation campaign. The contract
is valued at €3.135 million before VAT and €3.2604 million including taxes.

These commercial developments sit alongside earnings expectations that continue 
to place attention on Sanofi’s ability to convert its pharmaceutical portfolio into
higher per-share profit. Analyst estimates cited for 2026 point to earnings per 
share of $4.99, rising to $5.38 for 2027. Sanofi shares closed at $44.47 on 2 September
2026.

_**[Global Opportunities Trust](https://www.directorstalkinterviews.com/company/global-opportunities-trust-plc/got.l)
plc** (LON:GOT) invests globally in undervalued asset classes without reference 
to the composition of any stock market index._

Share on:
